NDA 021038 · Hospira
Precedex
Dexmedetomidine Hydrochloride · Injection
NovelLast checked: Nov 20, 2026Latest source record: May 1, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1999
Dec 17, 1999
Approved uses
5
Original approval plus efficacy supplements
Registered trials
1,922
279 Phase 3, 159 recruiting
FAERS reports
2,999
2,792 serious, 459 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 17, 2026.
PRECEDEX is a alpha 2 -adrenergic receptor agonist indicated for: • Sedation of initially intubated and mechanically ventilated adult patients during treatment in an intensive care setting. Administer PRECEDEX by continuous infusion not to exceed 24 hours. ( 1.1 ) • Sedation of non-intubated adult patients prior to and/or during surgical and other procedures. ( 1.2 ) • Sedation of non-intubated pediatric patients aged 1 month to less than 18 years prior to and during non-invasive procedures. ( 1.2 ) 1.1 Intensive Care Unit Sedation PRECEDEX is indicated for sedation of initially intubated and mechanically ventilated adult patients during treatment in an intensive care setting. PRECEDEX should be administered by continuous infusion not to exceed 24 hours. PRECEDEX has been continuously infused in mechanically ventilated adult patients prior to extubation, during extubation, and post-extubation. It is not necessary to discontinue PRECEDEX prior to extubation. 1.2 Procedural Sedation PRECEDEX is indicated for sedation of non-intubated adult patients prior to and/or during surgical and other procedures. PRECEDEX is indicated for sedation of non-intubated pediatric patients aged 1 month to less than 18 years prior to and during non-invasive procedures.
Mechanism: PRECEDEX is a relatively selective centrally acting alpha 2 -adrenergic agonist with sedative properties. Alpha 2 selectivity is observed in animals following slow intravenous infusion of low and medium doses (10-300 mcg/kg). Both alpha 1 and alpha 2 activity is observed following slow intravenous infusion of high doses (≥1,000 mcg/kg) or with rapid intravenous administration.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 16, 2022 Supplement 28 · Efficacy LabelLetter
- Jun 17, 2013 Supplement 21 · Efficacy · priority review LetterPediatric Written RequestPediatric Amendment 1
- Jun 17, 2013 Supplement 22 · Efficacy · priority review Pediatric Written RequestPediatric Amendment 1Pediatric Medical Review
- Oct 17, 2008 Supplement 10 · Efficacy Letter
- Dec 17, 1999 Original approval · Type 1 - New Molecular Entity LetterPediatric Written RequestPediatric Amendment 1
5 products under this application
- PRECEDEX · DEXMEDETOMIDINE HYDROCHLORIDE EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML) · INJECTABLE, INJECTION · Prescription · TE AP
- PRECEDEX · DEXMEDETOMIDINE HYDROCHLORIDE EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML) · INJECTABLE, INJECTION · Prescription · TE AP
- PRECEDEX · DEXMEDETOMIDINE HYDROCHLORIDE EQ 1MG BASE/250ML (EQ 4MCG BASE/ML) · INJECTABLE, INJECTION · Prescription · TE AP
- PRECEDEX · DEXMEDETOMIDINE HYDROCHLORIDE EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML) · INJECTABLE, INJECTION · Prescription · TE AP
- PRECEDEX · DEXMEDETOMIDINE HYDROCHLORIDE EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) · INJECTABLE, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Dexmedetomidine" as an intervention, any sponsor and status, largest first.
- Perioperative Dexmedetomidine and Long-term Survival After Cancer SurgeryPivotal-lookingRecruiting
Peking University First HospitalAcademic, hospital or other
NCT06030804 · 4,532 participants (planned) · Start Sep 12, 2023 · Primary completion Sep 2027
Drug: Dexmedetomidine; Placebo · For: Elderly; Cancer Surgery; Dexmedetomidine and 1 more
Sites: Hefei, China; Beijing, China; Chongqing, China · 40 sites in all
- Intranasal Dexmedetomidine and Perioperative Myocardial Injury in Patients Having Percutaneous Coronary InterventionsPivotal-lookingNot yet recruiting
Second Affiliated Hospital, Zhejiang University, School of MedicineAcademic, hospital or other
NCT07847580 · 2,500 participants (planned) · Start Sep 30, 2026 · Primary completion Jun 30, 2029
Drug: Intranasal dexmedetomidine; Normal Saline · For: Coronary Heart Disease; Coronary Artery Disease
Sites: Hangzhou, China
- Cognitive Outcomes After Dexmedetomidine Sedation in Cardiac Surgery PatientsPivotal-lookingRecruiting
Sunnybrook Health Sciences CentreAcademic, hospital or other
NCT04289142 · 2,400 participants (planned) · Start Dec 1, 2019 · Primary completion Jul 2028
Drug: Dexmedetomidine Hydrochloride Group · For: Delirium; Cognitive Dysfunction; Cognition Disorder and 14 more
Sites: Vancouver, Canada; London, Canada; Toronto, Canada · 8 sites in all
- Perioperative Multimodal Analgesia Protocol for Supratentorial CraniotomyPivotal-lookingNot yet recruiting
Beijing Tiantan HospitalAcademic, hospital or other
NCT06406829 · 2,000 participants (planned) · Start Feb 9, 2026 · Primary completion Dec 31, 2026
Drug: Dexmedetomidine; Normal saline · For: Postoperative Pain; Analgesia; Supratentorial Brain Tumor
- Perioperative Multimodal Analgesia for Supratentorial CraniotomyPivotal-lookingRecruiting
Beijing Tiantan HospitalAcademic, hospital or other
NCT07441421 · 2,000 participants (planned) · Start Mar 9, 2026 · Primary completion Dec 31, 2027
Drug: Dexmedetomidine · For: Postoperative Pain; Analgesia; Supratentorial Brain Tumor
Sites: Beijing, China
- Dexmedetomidine-esketamine and tDCS for Prevention of Neurocognitive Complications After SurgeryPivotal-lookingNot yet recruiting
Peking University First HospitalAcademic, hospital or other
NCT07576517 · 1,996 participants (planned) · Start Oct 2026 · Primary completion Dec 2029
Drug: Dex-Esk; Placebo · For: Older Patients; Surgery; Dexmedetomidine and 3 more
Sites: Beijing, China; Fuzhou, China; Shenzhen, China · 6 sites in all
- Long-term Follow-up of Dexmedetomidine-esketamine and tDCS for Neurocognitive Complications After SurgeryPivotal-lookingNot yet recruiting
Peking University First HospitalAcademic, hospital or other
NCT07576543 · 1,996 participants (planned) · Start Oct 2026 · Primary completion Dec 2030
Drug: Dex-Esk; Placebo · For: Older Patients; Surgery; Dexmedetomidine and 4 more
Sites: Beijing, China; Fuzhou, China; Shenzhen, China · 6 sites in all
- Comparison of Epidural Labor Analgesia With Dexmedetomidine or SufentanilPivotal-lookingStatus unknown
Fudan UniversityAcademic, hospital or other
NCT03622047 · 1,800 participants (planned) · Start Aug 15, 2018 · Primary completion Aug 1, 2020
Drug: Dexmedetomidine ropivacaine; No analgesia labor · For: Pharmacological Action
Sites: Shanghai, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- bradycardia258
- off label use238
- hypotension181
- cardiac arrest172
- pyrexia116
- drug ineffective107
- product use in unapproved indication101
- pneumonia100
- product use issue92
- drug interaction86
- oxygen saturation decreased86
- respiratory failure86
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 9 |
| 2005 | 10 |
| 2006 | 27 |
| 2007 | 21 |
| 2008 | 29 |
| 2009 | 34 |
| 2010 | 48 |
| 2011 | 59 |
| 2012 | 72 |
| 2013 | 86 |
| 2014 | 98 |
| 2015 | 104 |
| 2016 | 212 |
| 2017 | 188 |
| 2018 | 192 |
| 2019 | 238 |
| 2020 | 233 |
| 2021 | 207 |
| 2022 | 229 |
| 2023 | 270 |
| 2024 | 246 |
| 2025 | 258 |
| 2026 | 129 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Current · updated Nov 6, 2026
Precedex, Injection, 400 mcg/100 mL (NDC 0409-7853-24).
Current · updated Nov 6, 2026
Precedex, Injection, 200 mcg/50 mL (NDC 0409-7838-24).
Current · updated Nov 6, 2026
Precedex, Injection, 80 mcg/20 mL (4 mcg/mL) (NDC 0409-1660-20).
Current · updated Nov 6, 2026
Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-1660-50).
Current · updated Nov 6, 2026
Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-4596-20).
Current · updated Nov 6, 2026
Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-1174-10).
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Dexmedetomidine vs other sedatives in critically ill mechanically ventilated adults: a systematic review and meta-analysis of randomized trials.
Lewis K, Alshamsi F, Carayannopoulos KL, et al. · Intensive Care Med 2022 · Meta-Analysis, Systematic Review
- Dexmedetomidine for adult cardiac surgery: a systematic review, meta-analysis and trial sequential analysis.
Poon WH, Ling RR, Yang IX, et al. · Anaesthesia 2023 · Systematic Review, Meta-Analysis
- Dexmedetomidine for analgesia and sedation in newborn infants receiving mechanical ventilation.
Lim JY, Ker CJ, Lai NM, et al. · Cochrane Database Syst Rev 2024 · Systematic Review, Research Support, Non-U.S. Gov't
- Outcomes of dexmedetomidine versus propofol sedation in critically ill adults requiring mechanical ventilation: a systematic review and meta-analysis of randomised controlled trials.
Heybati K, Zhou F, Ali S, et al. · Br J Anaesth 2022 · Meta-Analysis, Systematic Review
- Efficacy of perioperative dexmedetomidine in postoperative pain and neurocognitive functions in orthopedic surgery: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials.
Zhang X, Leng Y, Yuan X, et al. · Int J Surg 2025 · Meta-Analysis, Systematic Review
- Pharmacological and non-pharmacological interventions to prevent delirium in critically ill patients: a systematic review and network meta-analysis.
Burry LD, Cheng W, Williamson DR, et al. · Intensive Care Med 2021 · Research Support, Non-U.S. Gov't, Systematic Review
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.